Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Genetic Disorders

pharma-news-for-applied-therapeutics-alnylam-rigel

Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Grants Fast Track for Lin BioScience’s LBS-007; Alnylam’s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS.

Explore More...
leading-investigational-drugs-pompe-disease

5 Promising Pompe Disease Drugs in Early-stage Development

5-promising-exosome-based-therapies

5 Promising Exosome-based Therapies Paving the Way for Personalized Medicine

Feature-Transforming Pompe Disease Care_ Pioneering Innovations and Strategic Advances in Treatment

Transforming Pompe Disease Care: Latest Innovations and Strategic Advances in Treatment

hypophosphatasia-treatment-market

Exploring Growth Opportunities in the Hypophosphatasia Treatment Market: Navigating the Ultra-rare Disease Landscape

Duchenne Muscular Dystrophy Market

Duchenne Muscular Dystrophy Market: What’s More Beyond Exon-Skipping Therapies?

Duchenne Muscular Dystrophy Advances Challenges and the Future of Treatment

Duchenne Muscular Dystrophy: Advances, Challenges, and the Future of Treatment

pfizers-dmd-gene-therapy

Gene therapy: Following Pfizer’s Unexpected Failure, Sarepta is celebrating its much-awaited full approval! Sarepta’s stock price has shot up over 32%

pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms

Takeda Showcase Phase III Results for Soticlestat; Imfinzi and Chemotherapy Combination Gains US Approval; Nipocalimab Shows Notable Efficacy in Phase II Study; Bristol Myers Squibb’s Augtyro FDA Approval; AstraZeneca’s Farxiga FDA Approval

pharma-news-for-x4-pharmaceuticals-ono-beigene-sanofi

X4 Pharmaceuticals’ XOLREMDI FDA Approval; ONO to Acquire Deciphera Pharmaceuticals; Johnson & Johnson’s SIRTURO CHMP Approval; BeiGene’s Tislelizumab EC Approval; Sanofi’s Rilzabrutinib LUNA 3 Phase III Trial

emerging-therapies-for-alport-syndrome-treatment

Breakthroughs in Alport Syndrome Treatment: A New Era of Hope

Navigating the Healthcare Horizon: Odyssey of Mergers, Funding, and Acquisitions in 2024

mrna-based-vaccines-and-therapeutics

Unleashing the Power of mRNA: A Revolutionary Approach to Vaccines and Therapeutics

Pharma News for Merck, BMS, Sanofi, Juvena

Merck’s KEYTRUDA as Adjuvant Therapy for RCC Patients; BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma for Multiple Myeloma; FDA Approves Dupixent for Eosinophilic Esophagitis; Juvena Receives FDA Orphan Drug Designation for JUV-161; European Commission Authorizes GSK’s Omjjara; ENHERTU Granted Priority Review in the US for for metastatic HER2-positive Solid Tumors

Pharma News for Exelixis, AstraZeneca, Kyverna

BMS, and Exelixis’s Opdivo + CABOMETYX in First-Line Advanced Renal Cell Carcinoma; AIRSUPRA Now Available as the First and Only FDA-approved Anti-inflammatory Rescue Option for Asthma; AstraZeneca’s Voydeya Receives First-ever Regulatory Approval; EMA Grants ODD to GC Biopharma’s Sanfilippo Syndrome (Type A) Treatment; FDA Approves NRx Pharma’s IND Application of NRX-101; FDA Fast Track Designation to Kyverna’s KYV-101

emerging-therapies-for-achondroplasia-treatment

Achondroplasia Treatment Space: Hunt for Potential Curative Therapies

A Glance at Key Insights From 42nd J.P. Morgan Annual Healthcare Conclave

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader